Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Darunavir 600 And 800 Mg
Generic Name
Darunavir
Active Ingredient
Darunavir HydrateCategory
Other
Variants
3
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 800 mg/1 | TABLET | ORAL | 69097-244 |
| 600 mg/1 | TABLET | ORAL | 69097-248 |
| 800 mg/1 | TABLET | ORAL | 63629-5686 |
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Darunavir 600 And 800 Mg, you must consult a qualified healthcare professional.
Detailed information about Darunavir 600 And 800 Mg
Darunavir Hydrate is a potent HIV-1 protease inhibitor used in combination with other antiretroviral agents to manage HIV infection in adults and pediatric patients. It requires co-administration with a booster like ritonavir or cobicistat to reach therapeutic levels.
The dosage of Darunavir Hydrate for adults depends heavily on whether the patient has previously taken HIV medications and whether their virus has specific resistance mutations.
Darunavir Hydrate is approved for children 3 years of age and older who weigh at least 10 kg (approximately 22 lbs). Dosing in children is strictly weight-based:
Note: Darunavir is not approved for use in infants under 3 years of age due to the risk of severe toxicity observed in animal studies.
For patients with kidney disease, Darunavir Hydrate generally does not require a dose adjustment because very little of the drug is cleared through the kidneys. However, if Darunavir is used in a combination pill containing tenofovir, renal monitoring is essential, and the combination may be contraindicated in severe renal failure.
Clinical trials did not include enough patients over 65 to determine if they respond differently. In general, dosing for elderly patients should be cautious, starting at the lower end of the range, reflecting the higher frequency of decreased hepatic, renal, or cardiac function.
If you miss a dose, timing is critical:
Symptoms of a Darunavir overdose are not well-documented but may include severe nausea, abdominal pain, or an intensification of side effects. If an overdose is suspected, contact a Poison Control Center or seek emergency medical attention immediately. There is no specific antidote for Darunavir; treatment consists of general supportive measures, including monitoring of vital signs.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as this can lead to drug resistance.
Most patients taking Darunavir Hydrate experience some side effects, especially during the first few weeks of treatment as the body adjusts to the medication. Common reactions include:
Darunavir Hydrate is a potent medication that requires careful management. It is only effective when taken as part of a complete antiretroviral regimen. Missing doses can lead to 'viral escape,' where the virus begins to replicate again and develops mutations that make it resistant not only to Darunavir but potentially to other drugs in the same class.
No FDA black box warnings for Darunavir Hydrate. However, clinicians treat the warnings for hepatotoxicity and severe skin reactions with equivalent gravity.
Darunavir Hydrate, when boosted with ritonavir or cobicistat, is a powerful inhibitor of the CYP3A enzyme. This means it can cause other drugs to build up to dangerous or fatal levels in your body. The following drugs must NEVER be used with Darunavir:
There are several scenarios where Darunavir Hydrate must NEVER be used because the risks far outweigh any potential benefits:
Darunavir Hydrate is an important component of HIV management during pregnancy to prevent mother-to-child transmission.
In the United States and other regions where clean water and infant formula are accessible, the CDC and health authorities recommend that individuals with HIV avoid breastfeeding to eliminate the risk of postnatal HIV transmission. Additionally, it is known that Darunavir is excreted in the milk of lactating rats; it is likely excreted in human milk, and the effects on a nursing infant are unknown.
Darunavir Hydrate is a non-peptidic HIV-1 protease inhibitor. It was specifically designed to form robust hydrogen bonds with the backbone of the HIV-1 protease enzyme. By binding to the enzyme's active site, it prevents the cleavage of Gag and Gag-Pol polyproteins. This inhibition results in the production of immature viral particles that lack the structural integrity and enzymatic machinery (like reverse transcriptase and integrase) needed to infect new host cells. Its unique structure allows it to maintain effectiveness against many viral strains that have developed resistance to older protease inhibitors like Saquinavir or Indinavir.
The relationship between the concentration of Darunavir and the suppression of HIV is well-established. The goal of therapy is to maintain a 'trough' concentration (the lowest level before the next dose) that is significantly higher than the EC50 (the concentration needed to inhibit 50% of the virus). Because Darunavir is 'boosted,' it provides a high genetic barrier to resistance, meaning the virus would need to develop multiple specific mutations simultaneously to overcome the drug's effect.
| Parameter | Value (Boosted with Ritonavir) |
Common questions about Darunavir 600 And 800 Mg
Darunavir Hydrate is a prescription medication used to treat Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and children at least 3 years of age. It belongs to a class of drugs known as protease inhibitors, which work by blocking an enzyme the virus needs to replicate itself. By lowering the amount of HIV in the blood, Darunavir helps the immune system stay stronger and reduces the risk of HIV-related complications. It is always used in combination with other HIV medicines and a 'booster' drug like ritonavir or cobicistat. It is not a cure for HIV or AIDS, but it helps manage the condition effectively.
The most common side effects reported by patients taking Darunavir Hydrate include diarrhea, nausea, headache, and abdominal pain. Many patients also experience a mild skin rash, which should be monitored closely by a doctor. Some people may notice changes in body fat distribution, such as increased fat in the upper back or stomach and thinning of the face or limbs. Laboratory changes, such as increased cholesterol or blood sugar levels, are also common. Most mild side effects improve as your body adjusts to the medication, but you should always report new symptoms to your healthcare provider.
There is no direct chemical interaction between Darunavir Hydrate and alcohol that would make moderate drinking strictly prohibited. However, both alcohol and Darunavir are processed by the liver, so heavy drinking can increase the risk of liver strain or toxicity. Furthermore, alcohol can sometimes interfere with your ability to remember to take your medication on time, which is crucial for preventing drug resistance. If you have pre-existing liver conditions like Hepatitis B or C, your doctor will likely advise you to limit or avoid alcohol entirely. Always discuss your lifestyle habits with your medical team.
Darunavir Hydrate is often used during pregnancy to keep the mother's viral load low and prevent transmission to the baby, but the dosing must be adjusted. Because drug levels naturally drop during pregnancy, healthcare providers typically switch patients to a twice-daily dosing schedule rather than once-daily. Cobicistat-boosted Darunavir is generally avoided in pregnancy due to inadequate drug levels. While studies haven't shown an increased risk of birth defects, the decision to use Darunavir is based on a careful risk-benefit analysis. Pregnant individuals should be closely monitored by an HIV specialist.
Darunavir Hydrate begins working to inhibit viral replication within hours of the first dose, but it takes time to see the results in your blood work. Most patients will see a significant drop in their 'viral load' within the first 4 to 8 weeks of consistent treatment. The goal is to reach an 'undetectable' viral load, which can take anywhere from 3 to 6 months depending on your starting level and adherence. Even if you feel better quickly, you must continue taking the medication exactly as prescribed to keep the virus suppressed. Regular testing will confirm how well the drug is working for you.
No, you should never stop taking Darunavir Hydrate suddenly unless your doctor tells you to do so because of a severe allergic reaction. Stopping HIV medication allows the virus to start replicating again immediately, often at a very fast rate. This 'rebound' increases the risk that the virus will develop mutations, making it resistant to Darunavir and other similar drugs in the future. If you are having trouble with side effects or the cost of the medication, talk to your healthcare provider. They can help you manage side effects or transition you to a different treatment regimen safely.
If you miss a dose of Darunavir Hydrate, what you should do depends on your specific dosing schedule. If you take it once daily and remember within 12 hours, take the missed dose with food immediately. If you take it twice daily and remember within 6 hours, take the missed dose with food right away. If more time has passed than these windows, skip the missed dose and take your next dose at the regular time. Never take two doses at once to make up for a missed one. Consistency is key to preventing the virus from becoming resistant to the medication.
Weight gain has been observed in some patients starting modern antiretroviral therapy, including regimens containing protease inhibitors like Darunavir. This is sometimes referred to as 'return to health' weight gain, as the body recovers from the effects of the HIV infection. However, protease inhibitors are also associated with metabolic changes and lipodystrophy, which is a redistribution of body fat. While Darunavir is generally considered to have a lower risk of significant weight gain compared to some newer integrase inhibitors, it can still affect your metabolism. Maintaining a healthy diet and exercise routine is recommended while on this medication.
Darunavir Hydrate has many significant drug interactions because it affects the liver enzymes that process other medicines. It must be taken with a 'booster' like ritonavir or cobicistat, but it can interact dangerously with cholesterol drugs (statins), blood thinners, certain antidepressants, and even herbal supplements like St. John's Wort. Some interactions can cause the other drugs to reach toxic levels, while others might make Darunavir less effective. You must provide your doctor and pharmacist with a complete list of all medications, vitamins, and supplements you take to ensure your combination is safe.
Yes, generic versions of Darunavir Hydrate (the active ingredient in Prezista) have become available in many regions, including the United States. Generic medications contain the same active ingredient and meet the same strict standards for quality and efficacy as the brand-name version. Using a generic can significantly reduce the cost of HIV treatment for many patients. Your pharmacist or insurance provider can tell you if a generic version is available for your specific dose and if it is covered by your plan. Regardless of whether you take the brand or generic, the requirement to take it with food and a booster remains the same.
> Warning: Stop taking Darunavir Hydrate and call your doctor immediately if you experience any of these serious reactions.
Currently, Darunavir Hydrate does not carry a specific FDA Black Box Warning. However, it does carry 'Warnings and Precautions' of the highest clinical significance regarding Hepatotoxicity and Severe Skin Reactions. The drug label emphasizes that patients with pre-existing liver dysfunction, including chronic active hepatitis B or C, have an increased risk for liver function abnormalities and should be monitored with frequent laboratory testing.
Report any unusual symptoms to your healthcare provider. Early detection of side effects is key to maintaining a successful long-term HIV treatment plan.
To ensure safety and efficacy, your healthcare provider will require regular blood work:
Darunavir Hydrate generally does not cause sedation or dizziness that would impair the ability to drive. However, some patients report fatigue or headaches. You should observe how the medication affects you before engaging in activities that require mental alertness.
There is no direct contraindication between alcohol and Darunavir Hydrate. However, both alcohol and Darunavir are processed by the liver. Excessive alcohol consumption can increase the risk of liver toxicity and may interfere with your ability to adhere to your medication schedule.
Never stop taking Darunavir Hydrate without consulting your doctor. If you stop the medication, the virus will likely rebound quickly. If you must stop due to a severe side effect, your doctor will need to manage the transition to a new regimen carefully to prevent the development of drug resistance.
> Important: Discuss all your medical conditions, especially liver disease, diabetes, or bleeding disorders, with your healthcare provider before starting Darunavir Hydrate.
Darunavir can cause asymptomatic elevations in serum amylase or lipase. It may also cause false-positive results in certain urine glucose tests if the patient has developed drug-induced hyperglycemia.
For each interaction, the management strategy usually involves either avoiding the second drug, adjusting the dose of the second drug, or intensive monitoring of blood levels and clinical symptoms.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter vitamins.
Relative contraindications require a careful risk-benefit analysis by a specialist:
Patients who have had severe skin rashes from other protease inhibitors (like Fosamprenavir or Tipranavir) should be treated with extreme caution, as there may be cross-sensitivity in how the body reacts to these chemically related structures.
> Important: Your healthcare provider will evaluate your complete medical history, including past drug allergies and liver health, before prescribing Darunavir Hydrate.
Darunavir is approved for children 3 years and older. It is not used in children younger than 3 because animal studies showed a high rate of mortality (death) in juvenile rats exposed to Darunavir, likely due to an immature blood-brain barrier and liver enzyme system. In older children, the drug is effective, but weight-based dosing must be strictly followed.
Patients over 65 may be at higher risk for side effects due to age-related declines in liver and kidney function. There is also a higher likelihood of polypharmacy (taking many medications), which increases the risk of dangerous drug interactions. Clinical monitoring should be more frequent in this population.
Darunavir is not significantly cleared by the kidneys. For patients with a GFR above 30 mL/min, no adjustment is needed. For those on dialysis, Darunavir is not expected to be removed by the procedure because it is highly protein-bound. Dosing remains the same, but the overall health of the patient must be monitored.
> Important: Special populations require individualized medical assessment and frequent follow-up to ensure both the safety of the patient and the suppression of the virus.
|---|---|
| Bioavailability | ~37% (increases with food/booster) |
| Protein Binding | 95% (primarily to AAG) |
| Half-life | 15 hours |
| Tmax | 2.5 to 4 hours |
| Metabolism | Hepatic (CYP3A4) |
| Excretion | Fecal 79.5%, Renal 13.9% |
Darunavir Hydrate is classified as an Antiretroviral, specifically a Protease Inhibitor (PI). It is often grouped with other PIs such as Atazanavir, Lopinavir, and Ritonavir, though it is considered more potent against resistant strains.